The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
Subjects with a confirmed diagnosis of IPF and pulmonary function meeting the protocol-specified criteria;
Subjects must agree to use highly effective contraception during the study and for 6 months after the last administration of the study drug;
Subjucts must be able to understand the study, voluntarily provide written informed consent, and be willing and able to comply with all study-related procedures.
Subjects with a history of drug or other allergies, or those judged by the investigator to be potentially allergic to the study drugs;
Presence of any other clinically significant pulmonary diseases besides IPF at screening;
Any known contraindications to performing pulmonary function tests at screening;
Respiratory or systemic infections requiring anti-infective therapy within 1 month prior to randomization;
Parallel
SV001
DrugSV001 ： Multiple-dose
Placebo
DrugPlacebo ： Multiple-dose
Incidence of Treatment-Emergent Adverse Events
Adverse event type, incidence, duration
Peak Plasma Concentration (Cmax)
PK (Pharmacokinetics)
Peak time（Tmax）
PK (Pharmacokinetics)
Area under the plasma concentration versus time curve (AUC)
PK (Pharmacokinetics)
half-life（T1/2）
PK (Pharmacokinetics)
Click on the lead sponsor to view all of their trials.
